2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-143477
    Factor XI-IN-1 2720619-72-5 98%
    Factor XI-IN-1 (Compound 27) is a factor XI activation inhibitor with an EC50 of 25.14 nM.
    Factor XI-IN-1
  • HY-143664
    (±)14(15)-DiHET 98%
    (±)14(15)-DiHET ((±)14,15-DiHETrE) is an epoxide hydrolases enzymatically hydrated metabolite of (±)14(15)-EET.
    (±)14(15)-DiHET
  • HY-143721
    SSAO inhibitor-2 2671028-06-9 98%
    SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC50s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc.
    SSAO inhibitor-2
  • HY-143723
    SSAO inhibitor-3 2671028-09-2 98%
    SSAO inhibitor-3 (Compound 2) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC50s of <10 nM, and 0.1-10 μM for human SSAO and AOC1, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc.
    SSAO inhibitor-3
  • HY-143886
    AD011 3010931-91-3 98%
    AD011 is a dual inhibitor of cACE/NEP. AD011 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD011 has the potential for providing the potent antihypertensive and cardioprotective benefits.
    AD011
  • HY-143887
    AD012 3010931-94-6 98%
    AD012 is a dual inhibitor of cACE/NEP. AD012 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD012 has the potential for providing the potent antihypertensive and cardioprotective benefits.
    AD012
  • HY-143888
    AD013 3010931-81-1 98%
    AD013 is a dual inhibitor of cACE/NEP. AD013 is synthesized based on the previously reported C-domain selective ACE inhibitor lisinopril-tryptophan. AD013 has the potential for providing the potent antihypertensive and cardioprotective benefits.
    AD013
  • HY-143890
    MRS4738 2801625-42-1 98%
    MRS4738 is a potent and high affinity P2Y14R antagonist. MRS4738 exhibits anti-hyperallodynic and antiasthmatic activity in vivo.
    MRS4738
  • HY-144658
    FXIa-IN-8 2744293-04-5 98%
    FXIa-IN-8 is a potent and selective FXIa inhibitor with an IC50 of 14.2 nM. FXIa-IN-8 shows antithrombotic activity without increasing the bleeding risk and obvious toxicitysup>[1].
    FXIa-IN-8
  • HY-144802
    DDO-02001 1186049-49-9 98%
    DDO-02001 is a moderately potent Kv1.5 potassium channel inhibitor with an IC50 value of 17.7 μM. DDO-02001 can be used for researching anti-arrhythmia.
    DDO-02001
  • HY-145284
    APJ receptor agonist 4 2762567-70-2 98%
    APJ receptor agonist 4 is a potent and orally active agonist of apelin receptor (APJ) with EC50 and Ki of 0.06 nM and 0.07 nM respectively. APJ receptor agonist 4 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 4 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 4 leads to improved cardiac function and can be used for researching the HF disease.
    APJ receptor agonist 4
  • HY-145349
    FXIa-IN-6 1551459-37-0 98%
    FXIa-IN-6 is a potent FXIa inhibitor with selectivity against most of the relevant serine proteases (Ki = 0.3 nM).
    FXIa-IN-6
  • HY-145354
    FXIa-IN-7 2488952-56-1 98%
    FXIa-IN-7 is a selective and orally bioavailable factor XIa inhibitor with an IC50 value of 0.4 nM.
    FXIa-IN-7
  • HY-145610
    Mepixetil 98%
    Mepixetil is a potent antagonist of angiotensin II receptor.
    Mepixetil
  • HY-145611
    Mopivabil 2988562-84-9 99.66%
    Mopivabil is the antagonist of angiotensin II receptor.
    Mopivabil
  • HY-145649
    Zilebesiran 2380166-33-4 98%
    Zilebesiran is a siRNA that reduce hepatic angiotensinogen levels through RNA interference. it is used for the study of mild to moderate Hypertension. Angiotensinogen is the predominant precursor of angiotensin peptides and a key regulator of systemic blood pressure.
    Zilebesiran
  • HY-145841
    5-HT2A receptor agonist-2 528525-37-3 98%
    5-HT2A receptor agonist-2 is a highly potent serotonin 5-HT2 receptor agonists. 5-HT2A receptor agonist-2 inspires 5-HT2A, 5-HT2B, and 5-HT2C with EC50 values of 1.7, 0.58, and 0.50 nM, respectively.
    5-HT2A receptor agonist-2
  • HY-146173
    KCa1.1 channel activator-1 98%
    KCa1.1 channel activator-1 (compound 1E), a Quercetin hybrid derivative, is a selective vascular KCa1.1 channel channel stimulator. KCa1.1 channel activator-1 also displays CaV1.2 channel blocking activity. KCa1.1 channel activator-1 exhibits weak myorelaxant activity.
    KCa1.1 channel activator-1
  • HY-146174
    KCa1.1 channel activator-2 98%
    KCa1.1 channel activator-2 (compound 3F), a Quercetin hybrid derivative, is a selective vascular KCa1.1 channel stimulator. KCa1.1 channel activator-2 exhibits potent myorelaxant activity.
    KCa1.1 channel activator-2
  • HY-146205
    ATX inhibitor 18 2402772-30-7 98%
    ATX inhibitor 18 is a potent ATX inhibitor with an IC50 value of 24.2 nM. ATX inhibitor 18 shows antiproliferative activity and anti-fibrosis activity. ATX inhibitor 18 suppresses collagen deposition in TGF-β-mediated cardiac fibrosis.
    ATX inhibitor 18
Cat. No. Product Name / Synonyms Application Reactivity